Skip to main content

Table 1 Characteristics of the study population (n = 124) and overall survival

From: Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy

Characteristics No. of Patients (%) No. of Deaths (%)* P MST (95% CI, month) P
Age    0.456   0.468
   ≤ 60 years 55 (44.4) 39 (70.9)   21.0 (13.0-32.0)  
   > 60 years 69 (56.6) 53 (76.8)   18.0 (13.0-26.0)  
Gender    0.175   0.046
   Female 57 (46.0) 39 (68.4)   26.0 (17.0-38.0)  
   Male 67 (54.0) 53 (79.1)   17.0 (12.0-22.0)  
Smoke    0.752   0.679
   Ever 114 (91.9) 85 (74.6)   20.0 (16.0-26.0)  
   Never 10 (8.1) 7 (70.0)   16.0 (11.0-18.0)  
Pack -year    0.542   0.861
   ≤ 40 60 (48.4) 46 (75.0)   19.0 (14.0-29.0)  
   > 40 64 (51.6) 46 (73.0)   20.0 (13.0-29.0)  
Histology    0.828   0.632
   Adenocarcinoma 40 (32.3) 31 (77.5)   20.0 (17.0-31.0)  
   Squamous cell 38 (31.6) 28 (73.7)   16.0 (12.0-25.0)  
   Others 46 (37.1) 33 (71.7)   24.0 (13.0-36.0)  
KPS    0.175   0.067
   90-100 38 (30.7) 24 (66.2)   22.0 (16.0-39.0)  
   80 67 (54.0) 53 (79.1)   20.0 (14.0-27.0)  
   < 80 19 (15.3) 15 (79.0)   13.0 (8.0-29.0)  
Stage    0.057   0.088
   IIIa 52 (41.9) 34 (65.4)   20.0 (16.0-39.0)  
   IIIb 72 (58.1) 58 (80.6)   17.0 (13.0-23.0)  
Chemotherapy    0.186   0.766
   Yes 112 (90.3) 85 (75.9)   20.0 (16.0-26.0)  
   No 12 (9.7) 7 (58.3)   17.0 (11.0-44.0)  
Radiotherapy dose    0.360   0.857
   < 70Gy 59 (47.6) 46 (78.0)   21.0 (16.0-33.0)  
   ≥ 70Gy 65 (52.4) 46 (70.8)   17.0 (12.0-24.0)  
  1. Abbreviations: MST, median survival time.
  2. * Percentage of deaths in each stratum.
  3. Chi -square test for difference in the distribution of deaths.
  4. Log-rank test for survival time in the univariate analysis.
\